Pages that link to "Q33611312"
Jump to navigation
Jump to search
The following pages link to Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. (Q33611312):
Displaying 50 items.
- IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis (Q24796707) (← links)
- RANK-RANKL signalling in cancer (Q26747442) (← links)
- Porphyromonas gingivalis suppresses adaptive immunity in periodontitis, atherosclerosis, and Alzheimer's disease (Q28071909) (← links)
- Osteoclast inhibitory lectin, a family of new osteoclast inhibitors (Q28507297) (← links)
- New approaches to the treatment of osteoporosis (Q34014336) (← links)
- Osteoclasts and odontoclasts: signaling pathways to development and disease (Q34127948) (← links)
- Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data (Q34182834) (← links)
- The application of genomic and molecular data in the treatment of chronic cancer pain (Q34207230) (← links)
- Basic and clinical aspects of osteoporosis in inflammatory bowel disease. (Q34225188) (← links)
- Reaching a genetic and molecular understanding of skeletal development (Q34611297) (← links)
- The TNF receptor superfamily: role in immune inflammation and bone formation (Q35176348) (← links)
- B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease (Q35222008) (← links)
- Signalling in osteoclasts and the role of Fos/AP1 proteins (Q35553533) (← links)
- The PCa Tumor Microenvironment (Q35603143) (← links)
- Chondrocytes-Specific Expression of Osteoprotegerin Modulates Osteoclast Formation in Metaphyseal Bone (Q36017881) (← links)
- Osteoclast precursors, RANKL/RANK, and immunology (Q36324916) (← links)
- Future anti-catabolic therapeutic targets in bone disease (Q36532578) (← links)
- Inflammatory bowel diseases as secondary causes of osteoporosis (Q36565219) (← links)
- Osteoclast fusion and regulation by RANKL-dependent and independent factors (Q36568536) (← links)
- Porphyromonas gingivalis infection-associated periodontal bone resorption is dependent on receptor activator of NF-κB ligand (Q36826931) (← links)
- Interference with immune-cell-mediated bone resorption in periodontal disease (Q36938527) (← links)
- Neural progenitor cell-mediated delivery of osteoprotegerin limits disease progression in a preclinical model of neuroblastoma bone metastasis (Q37127171) (← links)
- RANKL stimulates proliferation, adhesion and IL-7 expression of thymic epithelial cells (Q37184962) (← links)
- Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide. (Q37588746) (← links)
- Immune mediators in the tumor microenvironment of prostate cancer (Q37701076) (← links)
- Regulation of male fertility by bone. (Q37920942) (← links)
- Protein kinase C inhibitor, GF109203X attenuates osteoclastogenesis, bone resorption and RANKL-induced NF-κB and NFAT activity. (Q38943284) (← links)
- Association between RANK, RANKL and OPG polymorphisms with ACPA and erosions in rheumatoid arthritis: results from a meta-analysis involving three French cohorts. (Q39367844) (← links)
- Genetically regulated hepatic transcripts and pathways orchestrate haematological, biochemical and body composition traits. (Q39613444) (← links)
- Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity. (Q39812715) (← links)
- LTbetaR signaling induces cytokine expression and up-regulates lymphangiogenic factors in lymph node anlagen (Q39986041) (← links)
- The synergistic effect of peptidoglycan and lipopolysaccaride on osteoclast formation (Q40607226) (← links)
- Aspirin inhibits LPS-induced macrophage activation via the NF-κB pathway. (Q41051290) (← links)
- Effect of glycosphingolipids on osteoclastogenesis and osteolytic bone diseases. (Q42288514) (← links)
- Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: a Possible Role for RANK/RANKL Pathway. (Q42620930) (← links)
- Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase (Q43559838) (← links)
- Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study (Q44192941) (← links)
- Interactions among human immunodeficiency virus (HIV)-1, interferon-gamma and receptor of activated NF-kappa B ligand (RANKL): implications for HIV pathogenesis (Q45024312) (← links)
- The role of RANKL (TRANCE/TNFSF11), a tumor necrosis factor family member, in skeletal development: effects of gene knockout and transgenic rescue (Q46286533) (← links)
- A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response (Q46743257) (← links)
- Osteomimicry: How the Seed Grows in the Soil (Q47393289) (← links)
- A novel ex vivo culture model for inflammatory bone destruction (Q48000639) (← links)
- Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. (Q52661548) (← links)
- Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. (Q53612779) (← links)
- RANKL Triggers Treg-Mediated Immunoregulation in Inflammatory Osteolysis. (Q54149268) (← links)
- Porphyromonas gingivalis induces RANKL in T-cells. (Q54429503) (← links)
- Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis (Q57483541) (← links)
- NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1 (Q57675122) (← links)
- Maternal RANKL Reduces the Osteopetrotic Phenotype of Null Mutant Mouse Pups (Q58582775) (← links)
- Overview of RAW264.7 for osteoclastogensis study: Phenotype and stimuli (Q64071144) (← links)